SANA — Sana Biotechnology, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1770121 ·
Last close
$2.94
Market Cap
$881.62M
52W High
$6.55
52W Low
$2.61
ADV30
3,530,043
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -65,420,000 | -63,635,000 | 431,522,000 | 57,073,000 | 276,954,000 |
| Mar 2026 | 0 | — | -48,614,000 | -47,210,000 | 373,593,000 | 83,800,000 | 254,353,000 |
| Dec 2025 | 0 | — | -61,199,000 | -58,825,000 | 416,890,000 | 71,870,000 | 256,006,000 |
| Sep 2025 | 0 | — | -43,515,000 | -42,152,000 | 435,432,000 | 103,357,000 | 240,124,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-132,550,000
Investing CF
$-7,404,000
Financing CF
$127,623,000
CapEx
$-1,338,000
Dividends Paid
—
Buybacks
$-60,000
EPS Diluted TTM
$-0.93
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,896,226,000
Inventory
—
Receivables
—
ST Investments
$17,336,000
EBIT TTM
$-203,692,000
Pretax Income TTM
$-241,987,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -205,708,000 | -244,166,000 | 416,890,000 | 256,006,000 | 160,884,000 | -143,828,000 |
| Dec 2024 | 0 | -270,832,000 | -266,759,000 | 501,020,000 | 250,516,000 | 250,504,000 | -223,153,000 |
| Dec 2023 | 0 | -286,127,000 | -283,255,000 | 565,299,000 | 277,793,000 | 287,506,000 | -253,582,000 |
| Dec 2022 | 0 | -272,564,000 | -269,476,000 | 822,720,000 | 323,405,000 | 499,315,000 | -290,050,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-50,291,000
OpCashFlow TTM
$0
Assets (Latest)
$501,020,000
Forward EPS
$-0.56
Max Pain — expiry 2026-10-16
max pain strike: $2.50 · spot: $2.92 · call oi: 8,315 · put oi: 769
Expected Move to 2026-10-16:
±$0.55
(18.84%) —
implied range
$2.37 –
$3.47
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLBT | SL Science Holding Ltd | $880.39M | $1.57 | — |
| CGEM | Cullinan Therapeutics, Inc. | $910.19M | $14.81 | — |
| CADL | Candel Therapeutics, Inc. | $843.23M | $11.02 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $799.38M | $14.47 | — |
| ODTX | Odyssey Therapeutics, Inc. | $985.68M | $20.51 | — |
News headlines (Yahoo Finance, 1h cache)
Sana Biotechnology to Present at September 2026 Investor Conferences
2026-09-01 20:05 · Yahoo
Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM
2026-07-16 21:11 · Yahoo
Sana (SANA) Upgraded to Buy: Here's What You Should Know
2026-07-15 16:00 · Yahoo
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
2026-07-01 13:00 · Yahoo
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
2026-05-15 13:00 · Yahoo
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
2026-05-12 20:05 · Yahoo
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
2026-05-11 20:05 · Yahoo
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
2026-05-05 20:05 · Yahoo
Sana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 Diabetes
2026-04-27 06:22 · Yahoo
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
2026-04-27 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.